We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
England’s Department of Health and NHS England have failed to manage the Cancer Drug Fund effectively by not carrying out its intended purpose and significantly outspending its budget, according to a report released by the UK Parliament’s House of Commons. Read More
Sens. Joe Manchin (D-W.Va) and Edward Markey (D-Mass.) will maintain their holds on the nomination of Robert Califf for the top job at the FDA, despite the agency’s announcement Thursday that it would overhaul its opioid policies. Read More
FDA reviewers have given their support to Celltrion’s proposed biosimilar for Remicade, finding no clinically meaningful differences between the copy and the original. Read More
Massachusetts Attorney General Maura Healey is mulling legal action against Gilead Sciences over its sky-high prices for two hepatitis C medications, alleging that the company’s approach could violate the state’s antitrust laws. Read More
The war on high pharmaceutical prices continues, with PBM Express Scripts taking aim at what it calls an excessive price jump for Valeant Pharmaceuticals’ diabetes drug Glumetza. Read More
After serving as Gilead Sciences’ CEO for 20 years, John C. Martin has announced that he is stepping down and will assume the role of executive chairman of the company. Read More
The EMA’s Committee for Medicinal Products for Human Use has recommended six new medicines for marketing authorization, including three innovators and three generics. Read More